Medlab Clinical (Medlab Clinical) Gross-Profit-to-Asset % : 5.42% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Medlab Clinical Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Medlab Clinical's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.06 Mil. Medlab Clinical's average Total Assets over the quarter that ended in Dec. 2023 was $1.18 Mil. Therefore, Medlab Clinical's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 5.42%.

Medlab Clinical Gross-Profit-to-Asset % Historical Data

The historical data trend for Medlab Clinical's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical Gross-Profit-to-Asset % Chart

Medlab Clinical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

10.19

0.23

7.95

5.59

10.66

Medlab Clinical Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial												3.33	9.08	12.29	9.87	5.42

Competitive Comparison of Medlab Clinical's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Medlab Clinical's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medlab Clinical's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's Gross-Profit-to-Asset % falls into.

Medlab Clinical Gross-Profit-to-Asset % Calculation

Medlab Clinical's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	0.538	/	( (7.988	+	2.11)	/ 2 )
	=	0.538	/	5.049
	=	10.66 %

Medlab Clinical's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0.064	/	( (2.11	+	0.252)	/ 2 )
	=	0.064	/	1.181
	=	5.42 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Medlab Clinical Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (Medlab Clinical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (OTCPK:MDBBF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.